Status:
COMPLETED
Pulmonary Vasculopathy Under Second-line Therapy of Chronic Myeloid Leukemia
Lead Sponsor:
Medical University of Graz
Conditions:
Chronic Myeloid Leukemia
Eligibility:
All Genders
18-95 years
Brief Summary
Chronic myelogenous leukemia (CML) is a chronic myeloproliferative disorder characterized by a translocation between chromosome 9 and 22, leading to a pathogenic tyrosine kinase signal transduction pr...
Detailed Description
Doppler echocardiography at rest will be performed in each patient. Patients without exercise capacity limitation an exercise test (Doppler echocardiography with spiroergometry) will be performed. Pat...
Eligibility Criteria
Inclusion
- patients with chronic myeloid leukemia under second-line therapy with dasatinib or nilotinib
- written informed consent
Exclusion
- Manifest pulmonary hypertension
- significant pulmonary disease
- Left-sided heart failure or diastolic compliance dysfunction +
- Hemodynamic relevant valvular disease
- Systemic arterial hypertension (at rest systolic \>150 mmHg, diastolic \> 90 mmHg, during exercise \> 220 mmHg)
- Severe anemia
- Uncontrolled supraventricular and ventricular arrhythmias
- Myocardial infarction (within the last 12 months)
- Pulmonary embolism (within the last 12 months)
- Recent therapy changes (within the last 12 months)
- Recent major surgeries (within the last 12 months)
- For exercise tests: musculoskeletal diseases which may unable the exercise tests.
Key Trial Info
Start Date :
July 1 2012
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 1 2015
Estimated Enrollment :
16 Patients enrolled
Trial Details
Trial ID
NCT01805843
Start Date
July 1 2012
End Date
June 1 2015
Last Update
September 9 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Medical University of Graz, Division of Pulmonology
Graz, Austria, 8036